TGF-β1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts

International Journal of Molecular Medicine

Volumn 22, Issue 1, 2008, Pages 55-60

  Sadick, Haneen ^a   Herberger, A ^a   Riedel, K ^b   Bran, G ^a   Goessler, U ^a   Hoermann, K ^a   Riedel, F ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Fibroblasts; Keloid; Matrix metalloproteinases; Transforming growth factor 1

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA1; MESSENGER RNA;

ANTISENSE THERAPY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; EAR LOBE; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROBLAST CULTURE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KELOID; MULTIPLEX POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN TARGETING; CELL FRACTIONATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY;

FIBROBLASTS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; KELOID; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; SUBCELLULAR FRACTIONS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 52049102028     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.22.1.55     Document Type: Article

References (43)

1. Kamamoto F, Paggiaro AO and Rodas A: A wound contraction experimental model for studying keloids and wound-healing modulators: Artif Organs 27: 701-705, 2003.
2. Slemp AE, Kirschner RE, Bettinger DA, Yager DR, Diegelmann RF and Cohen IK: The effect of TGF-β on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 98: 827-833, 1996.
3. Kuo YR, Wu WS, Jeng SF, Wang FS, Huang HC, Lin CZ and Yang KD: Suppressed TGF-beta1 expression is correlated with up-regulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med 36: 38-42, 2005.
4. Sato M: Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. Acta Derm Venereol 86: 300-307, 2006.
5. Slemp A and Kirschner RE: Keloids and scars: a review of keloids and scars, their pathogenesis, risk factors, and management. Curr Opin Pediatr 18: 396-402, 2006.
6. Wall SJ, Bevan D, Thomas DW, Harding KG, Edwards DR and Murphy G: Differential expression of matrix metalloproteinases during impaired wound healing of the diabetic mouse. J Invest Dermatol 119: 91-98, 2002.
7. Thielitz A, Vetter RW, Schultze B, et al: Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 128: 855-866, 2008.
8. Ravanti L, Häkkinen L, Larjava H, Saarialho-Kere U, Foschi M, Han J and Kähäri VM: Transforming growth factor-beta induces collagenase-3 expression by human gingival fibroblasts via p38 mitogen-activated protein kinase. J Biol Chem 274: 37292-37300, 1999.
9. Saed GM, Zhang W and Diamond MP: Effect of hypoxia on stimulatory effect of TGF-beta 1 on MMP-2 and MMP-9 activities in mouse fibroblasts. J Soc Gynecol Investig 7: 348-354, 2000.
10. Yuan W and Varga J: Transforming growth factor-beta repression of matrix metalloproteinase-1 in dermal fibroblasts involves Smad3. J Biol Chem 276: 38502-38510, 2001.
11. Philipp K, Riedel F, Germann G, Hormann K and Sauerbier M: TGF-β antisense oligonucleotides reduce mRNA expression of matrix metalloproteinases in cultured wound-healing-related cells. Int J Mol Med 15: 299-303, 2005.
12. Philipp K, Riedel F, Sauerbier M, Hormann K and Germann G: Targeting TGF-β in human keratinocytes and its potential role in wound healing. Int J Mol Med 14: 589-593, 2004.
13. Riedel K, Riedel F, Goessler UR, Germann G and Sauerbier M: TGF-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. Arch Med Res 38: 45-51, 2007.
14. Tuan TL and Nichter LS: The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 4: 19-24, 1998.
15. Chen MA and Davidson TM: Scar management: prevention and treatment strategies. Curr Opin Otolaryngol Head Neck Surg 13: 242-247, 2005.
16. Pollack SV and Goslen JB: The surgical treatment of keloids. J Dermatol Surg Oncol 8: 827-833, 1982.
17. Murray JC: Keloids and hypertrophic scars. Clin Dermatol 12: 27-37, 1994.
18. Williams RL and Armstrong DG: Wound healing. New modalities for a new millennium. Clin Podiatr Med Surg 15: 117-128, 1998.
19. Riedel K, Riedel F, Goessler UR, Holle G, Germann G and Sauerbier M: Current status of genetic modulation of growth factors in wound repair. Int J Mol Med 17: 183-193, 2006.
20. Hernandez A and Evers BM: Functional genomics: clinical effect and the evolving role of the surgeon. Arch Surg 134: 1209-1215, 1999.
21. Younai S, Nichter LS, Wellisz T, Reinisch J, Nimni ME and Tuan TL: Modulation of collagen synthesis by transforming growth factor-β in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 33: 148-151, 1994.
22. Lee TY, Chin GS, Kim WJ, Chan D, Gittes GK and Longaker MT: Expression of transforming growth factor beta 1, 2 and 3 proteins in keloids. Ann Plast Surg 43: 179-184, 1999.
23. Falanga V: Chronic wounds: pathophysiologic and experimental consideration. J Invest Dermatol 100: 721-725, 1993.
24. Ask K, Bonniaud P, Maass K, Eickelberg O, Margetts PJ, Warburton D, Groffen J, Gauldie J and Kolb M: Progressive pulmonary fibrosis is mediated by TGF-beta isoform 1 but not TGF-beta3. Int J Biochem Cell Biol 40: 484-495, 2008.
25. Agren MS: Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds. Arch Dermatol Res 291: 583-590, 1999.
26. Pattison PS: The importance of reassessment to chronic wound care. Ostomy Wound Manage 47: 24-25, 2001.
27. Kähäri VM and Saarialho-Kere U: Matrix metalloproteinases in skin. Exp Dermatol 6: 199-213, 1997.
28. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW and Ting K: Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 105: 638-647, 2000.
29. Al-Attar A, Mess S, Thomassen JM, Kauffman CL and Davison SP: Keloid pathogenesis and treatment. Plast Reconstr Surg 117: 286-300, 2006.
30. Neely AN, Clendening CE, Gardner J, et al: Gelatinase activity in keloids and hypertrophic scars. Wound Repair Regen 7: 166-171, 1999.
31. Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM and Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292: 988-994, 2000.
32. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT Jr, Hobson RW II, Duran WN and Pappas PJ: Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34: 930-938, 2001.
33. Shah M, Foreman DM and Ferguson MWJ: Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous wounds reduces scarring. J Cell Sci 108: 983-1002, 1995.
34. Pirollo KF, Rait A, Sleer LS and Chang EH: Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 99: 55-77, 2003.
35. Wacheck V: Oligonucleotide therapeutics - an emerging novel class of compounds. Wien Med Wochenschr 156: 481-487, 2006.
36. Wraight CJ and White PJ: Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 90: 89-104, 2001.
37. Schiavone N, Donnini M, Nicolin A and Capaccioli S: Antisense oligonucleotide drug design. Curr Pharm Des 10: 769-784, 2004.
38. Mirabelli CK, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 6: 647-661, 1991.
39. Choi BM, Kwak HJ, Jun CD, Park SD, Kim KY, Kim HR and Chung HAT: Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides. Immunol Cell Biol 74: 144-150, 1996.
40. Wahl SM, Allen JB, Costa GL, Wong HL and Dasch JR: Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med 177: 225-230, 1993.
41. Border WA and Ruoslahti E: Transforming growth factor-beta 1 induces extracellular matrix formation in glomerulonephritis. Cell Differ Dev 32: 425-431, 1990.
42. Field AK and Goodchild J: Antisense oligonucleotides: rational drug design for genetic pharmacology. Exp Opin Invest Drugs 4: 799-821, 1995.
43. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D and Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17: 3586-3595, 1999.